An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension

Journal of the American Society of Hypertension

Volumn 8, Issue 9, 2014, Pages 614-623

  Mirhafeza, Seyed Reza ^a   Mohebati, Mohsen ^a   Disfani, Mahboobeh Feiz ^a   Karimian, Maryam Saberi ^b   Ebrahimi, Mahmoud ^a   Avan, Amir ^b,c   Eslami, Saied ^b,d   Pasdar, Alireza ^b,e   Rooki, Hassan ^b   Esmaeili, Habibollah ^b   Ferns, Gordon A ^f   Ghayour Mobarhan, Majid ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Blood pressure; Growth factors; Inflammation

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; VASCULOTROPIN A;

ADULT; ARM CIRCUMFERENCE; ARTICLE; BIOCHIP; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; IMMUNOASSAY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CYTOKINES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; HYPERTENSION; IMMUNOASSAY; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922194135     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.05.007     Document Type: Article

References (58)

1. Breslow JL. Cardiovascular disease burden increases, NIH funding decreases. Nat Med 1997;3:600-1.
2. Fernandez RP, Kaski JC. Interleukin-10 and coronary disease. Rev Esp Cardiol 2002;55(7):738-50.
3. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol 2012; 205(2):209-23.
4. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106: 506-12.
5. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women the women's health and aging study. Circulation 2001;103(7):947-53.
6. Yang X, Jansson P-A, Nagaev I, Jack MM, Carvalho E, Sunnerhagen KS, et al. Evidence of impaired adipogen-esis in insulin resistance. Biochem Biophys Res Com-mun 2004;317(4):1045-51.
7. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogen-esis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89(2):463-78.
8. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK. A high plasma concentration of TNF-a is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999; 54(7):M357-647.
9. Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol 2001;24:253-6.
10. Simiti A, Vida-Simiti L, Cristea A, Olinic N. Increased plasma levels of interleukin-8 in patients with unstable angina pectoris. Rom J Intern Med 1997;36(1-2): 47-56.
11. Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, Bingham SA, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2004; 24(8):1503-8.
12. Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther 2000;11(12):1731-41.
13. Tonkin A. Atherosclerosis and heart disease: Informa Health Care, Chapter 2; 2003. P. 13.
14. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet 2005; 365(9455):217-23.
15. Ebrahimi M, Kazemi-Bajestani SMR, Ghayour-Mobarhan M, Moohebati M, Paydar R, Azimi-Nezhad M, et al. Metabolic syndrome may not be a good predictor of coronary artery disease in the Iranian population: population-specific definitions are required. The Scientific World Journal 2009;9:86-96.
16. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, et al. 1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17(2):151-83.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112(17): 2735-52.
18. Bautista L, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-a) and essential hypertension. J Hum Hypertens 2005;19(2): 149-54.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-71.
20. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framing-ham Study. JAMA 1986;256(20):2835-8.
21. Molloy RM, Mc Connell RI, Lamont JV, FitzGerald SP. Automation of biochip array technology for quality results. Clin Chem Lab Med 2005; 43(12):1303-13.
22. FitzGerald SP, Lamont JV, McConnell RI, Benchikh EO. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005;51(7): 1165-76.
23. Azizi A, Abasi M, Abdoli G. The prevalence of hypertension and its association with age, sex and BMI in a population being educated using community-based medicine in Kermanshah: 2003. Iranian Journal of Endocrinology and Metabolism 2008;10(4): 323-9.
24. Hedayati M. Central obesity as a reliable predictor for hypertension and dyslipidemia: Tehran Lipid Glucose Study. Iranian Journal of Endocrinology and Metabolism 2010;12(3):251-9.
25. Ghavami H, Ahmadi F, Entezami H, Meamarian R. The effect of continuous care model on diabetic patients' blood pressure. Iranian Journal of Medical Education 2006;6(2):87-95.
26. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin chem 1999; 45(11):1967-73.
27. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
28. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A. Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res 2002;25(3):475-80.
29. Mendall M, Patel P, Asante M, Ballam L, Morris J, Strachan D, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997;78(3):273-7.
30. Yudkin JS, Stehouwer C, Emeis J, Coppack S. C-Reac-tive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19(4): 972-8.
31. Fernandez-Real J-M, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin En-docrinol Metab 2001;86(3):1154-9.
32. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J Am Soc Hypertens 2007;1(2):113-9.
33. Ito H, Ohshima A, Tsuzuki M, Ohto N, Takao K, Hijii C, et al. Association of serum tumour necrosis factor-a with serum low-density lipoprotein-choles-terol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol 2001;28(3): 188-92.
34. Sheu WHH, Lee WJ, Chang RL, Chen YT. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exp Hypertens 2000; 22(6):595-606.
35. Fernandez-Real J-M, Lainez B, Vendrell J, Rigla M, Castro A, Penarroja G, et al. Shedding of TNF-a receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2002;282(4):E952-9.
36. Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73(1):205-9.
37. Woods A, Brull D, Humphries S, Montgomery H. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21(19):1574-83.
38. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997;18:428-32.
39. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96(9):3042-7.
40. Li J-J, Li Y-S, Chu J-M, Zhang C-Y, Wang Y, Huang Y, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipid-emia. Clin Chim Acta 2006;366(1):269-73.
41. Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup JA. Taql polymorphism in the human interleukin-1b (IL-1b) gene correlates with IL-1b secretion in vitro. Eur J Clin Invest 1992;22(6):396-402.
42. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86(2):515-81.
43. Makki N, Thiel KW, Miller FJ Jr. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci 2013;14(10):20597-613.
44. Schlich R, Willems M, Greulich S, Ruppe F, Knoefel WT, Ouwens DM, et al. VEGF in the crosstalk between human adipocytes and smooth muscle cells: depot-specific release from visceral and perivascular adipose tissue. Mediators Inflamm 2013;2013.
45. Zhao Q, Ishibashi M, Hiasa KI, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004;44(3):264-70.
46. Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, Ichinose K, et al. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006;19(7): 718-27.
47. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells. Reproduction 2008;136(1): 125-30.
48. Pan P, Fu H, Zhang L, Huang H, Luo F, Wu W, et al. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol 2010;11(1):36.
49. Azimi-Nezhad M, Stathopoulou MG, Bonnefond A, Rancier M, Saleh A, Lamont J, et al. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine 2013;61(2):602-7.
50. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005;23: 995-1000.
51. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol 2002;83:13-21.
52. Capers Q, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, et al. Monocyte chemoattrac-tant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997;30(6):1397-402.
53. Chen FQ, Wang J, Liu XB, Ma XY, Zhang XB, Huang T, et al. Levels of inflammatory cytokines in type 2 diabetes patients with different urinary albumin excretion rates and their correlation with clinical variables. J Diabetes Res 2013;2013:138969.
54. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4 T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150(11):4754-65.
55. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, et al. Differential expression of three T lymphocyte activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999;104: 1041-50.
56. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:168.
57. Zou CJ, Liu JD, Zhou YC. Roles of central interleukin-1 on stress-induced-hypertension and footshock-induced-analgesia in rats. Neurosci Lett 2001;311(1): 41-4.
58. Voelkel NF, Tuder RM, Bridges J, Arend WP. Inter-leukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994;11(6):664-75.